risks of glp 1 medications Why do patients stop GLP-1 drugs? Glucagon-like Receptor-1 agonists for obesity:

Int J Dev Neurosci 37:5257 Furukawa S, Yang L, Sameshima H, Ikenoue T (2014) Repetitive administration of acetylcholine receptor agonist rescues brain inflammation and brain damage after hypoxia-ischemia in newborn rat

Many patients feel the benefits immediately and enjoy the boost of nutrients

2.3 Experimental and clinical evidence The current research evidence covers many levels such as cellular models, animal studies, and clinical samples, suggesting that ferroptosis plays an important pathogenic role in kidney injury associated with DKD

Summary: Researchers unmasked a slight, statistically measurable increase in the risk of developing a rare, potentially permanent blinding condition known as ischemic optic neuropathy (a sudden restriction of blood flow to the optic nerve) among patients initiating GLP-1 therapy compared to standard diabetes regimens

More targeted research is needed to establish direct mechanisms